Cambridge-based medical diagnostic specialist Lab21 performs tests to support personalised medicine and cancer care, and manufactures and distributes kits for infectious diseases that it sells to customers like the NHS, Red Cross, and pharmaceuticals firms. Founded in 2005 by biotech entrepreneur Professor Sir Christopher Evans, the company credits international expansion for its sales growth, as well as seven acquisitions it has made in the past two years. Under chief executive Graham Mullis, sales grew 47% a year from £3.6m in 2008 to £11.4m in 2011. It is backed by private equity firms including Nexus Medical Partners, Medicis Capital, and Merlin Biosciences Fund.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.